EGFR and non-small cell lung carcinoma: The present meta-analysis suggested that first-generation EGFR-TKI adjuvant therapy can improve OS in patients with stage III EGFR-mutant NSCLC, but had no impact on OS for stage IB-II NSCLC patients.